Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis

Tian,Muyou; Zhong,Yahua; Zhou,Fuxiang; Xie,Conghua; Zhou,Yunfeng; Liao,Zhengkai

doi:10.3892/mco.2015.518

Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis

Authors:
- Muyou Tian
- Yahua Zhong
- Fuxiang Zhou
- Conghua Xie
- Yunfeng Zhou
- Zhengkai Liao
View Affiliations

Affiliations: Department of Radiation Oncology and Medical Oncology, Hubei Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430000, P.R. China
Published online on: February 26, 2015 https://doi.org/10.3892/mco.2015.518
Pages: 720-724

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the effect of platinum‑based therapy on the short‑term efficacy and survival rate in patients with triple‑negative breast cancer (TNBC). A search of available databases was conducted, based on specific inclusion and exclusion criteria, for trials conducted between January 2006 and January 2014. The bibliographies of the included studies were examined with the same criteria. Included studies were evaluated using Grading of Recommendations Assessment, Development and Evaluation (GRADE), and extracted data were analyzed using RevMan 5.1 and GRADEprofiler 3.6. Eight studies with a total of 1,349 patients were included. The meta‑analysis revealed that the pathological complete response rate and overall response rate in TNBC patients who were treated with a platinum‑based regimen was significantly higher than that in those treated with a non‑platinum‑based regimen (49.2 and 64.3%, respectively). The disease‑free survival rate and overall survival rate were not significantly different between TNBC patients treated with a platinum‑based regimen and those treated with a non-platinum-based regiment (P>0.05). Platinum‑based chemotherapy in TNBC patients resulted in improved short‑term efficacy. Platinum-based regimens may therefore be more sensitive to TNBC patients. However, future multicenter randomized controlled trials are required to validate these findings and to determine whether platinum‑based chemotherapy can extend the survival rate of TNBC patients.

View Figures

View References

1	Reis-Filho JS and Tutt AN: Triple negative tumours: a critical review. Histopathology. 52:108–118. 2008. View Article : Google Scholar : PubMed/NCBI
2	Masuda H, Masuda N, Kodama Y, et al: Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol. 67:911–917. 2011. View Article : Google Scholar : PubMed/NCBI
3	Chang HR, Glaspy J, Allison MA, et al: Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 116:4227–4237. 2010. View Article : Google Scholar : PubMed/NCBI
4	Cheang MC, Voduc D, Bajdik C, et al: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 14:1368–1376. 2008. View Article : Google Scholar : PubMed/NCBI
5	Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
6	Tassone P, Di Martino MT, Ventura M, et al: Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther. 8:648–653. 2009. View Article : Google Scholar : PubMed/NCBI
7	Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR and Bishop DK: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 275:23899–23903. 2000. View Article : Google Scholar : PubMed/NCBI
8	Quinn JE, Kennedy RD, Mullan PB, et al: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63:6221–6228. 2003.PubMed/NCBI
9	Kennedy RD, Quinn JE, Mullan PB, Johnston PG and Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 96:1659–1668. 2004. View Article : Google Scholar : PubMed/NCBI
10	Moynahan ME, Chiu JW, Koller BH and Jasin M: Brca1 controls homology-directed DNA repair. Mol Cell. 4:511–518. 1999. View Article : Google Scholar : PubMed/NCBI
11	Rodler E, Korde L and Gralow J: Current treatment options in triple negative breast cancer. Breast Dis. 32:99–122. 2010.PubMed/NCBI
12	Chacón RD and Costanzo MV: Triple-negative breast cancer. Breast Cancer Res. 12 Suppl 2:32010. View Article : Google Scholar
13	Andre F and Zielinski CC: Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 23 Suppl 6:vi46–vi51. 2012. View Article : Google Scholar : PubMed/NCBI
14	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
15	Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with brca1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 28:375–379. 2010. View Article : Google Scholar : PubMed/NCBI
16	Byrski T, Huzarski T, Dent R, et al: Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 115:359–363. 2009. View Article : Google Scholar : PubMed/NCBI
17	Livasy CA, Perou CM, Karaca G, et al: Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 38:197–204. 2007. View Article : Google Scholar : PubMed/NCBI
18	Alba E, Chacon JI, Lluch A, et al: A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat. 136:487–493. 2012. View Article : Google Scholar : PubMed/NCBI
19	von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (geparsixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 15:747–756. 2014. View Article : Google Scholar : PubMed/NCBI
20	Sikov WM, Berry DA, Perou CM, et al: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhang P, Yin Y, Xu B, et al: Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer – a phase ii clinical trial. Cancer Res. 73:P3-14-072013. View Article : Google Scholar
22	Fan Y, Xu BH, Yuan P, et al: Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol. 24:1219–1225. 2013. View Article : Google Scholar : PubMed/NCBI
23	Wu Sk, Zhao X, Meng XY, et al: Analysis of chemotherapeutic efficacies in metastatic triple-negative breast cancer. Zhonghua Yi Xue Za Zhi. 13:3001–3003. 2012.
24	Bhattacharyya GS, Basu S, Agarwal V, et al: Single institute phase ii study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple-negative. Eur J Cancer (Abstr 41LBA, presented data-ECCO 15-ESMO 34 2009). 7:2009.
25	Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Pena-Curiel O, Baez-Revueltas B, et al: Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Res Treat. 146:567–572. 2014. View Article : Google Scholar : PubMed/NCBI
26	Turner NC, Reis-Filho JS, Russell AM, et al: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 26:2126–2132. 2007. View Article : Google Scholar : PubMed/NCBI
27	Leong CO, Vidnovic N, DeYoung MP, Sgroi D and Ellisen LW: The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest. 117:1370–1380. 2007. View Article : Google Scholar : PubMed/NCBI
28	Tun NM, Villani G, Ong K, Yoe L and Bo ZM: Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet. 85:43–48. 2014. View Article : Google Scholar : PubMed/NCBI
29	Liu M, Mo QG, Wei CY, Qin QH, Huang Z and He J: Platinum-based chemotherapy in triple-negative breast cancer: a meta-analysis. Oncol Lett. 5:983–991. 2013.PubMed/NCBI
30	ISRCTN Registry: Triple Negative Trial: a randomised phase III trial of carboplatin compared to docetaxel for patients with advanced oestrogen receptor-progesterone receptor-human epidermal growth factor receptor two-breast cancer. https://www.isrctn.com/ISRCTN97330959Accessed. July 4–2014
31	ClinicalTrials.gov, . Platinum for triple-negative metastatic breast cancer and evaluation of p63/p73 as a biomarker of response. https://clinicaltrials.gov/ct2/show/NCT00483223Accessed. July 4–2014